Perspectives in the treatment of pancreatic adenocarcinoma

Table 1 Controlled trials in adjuvant chemoradiotherapy for pancreatic ductal adenocarcinoma

Study name	No. of patients enrolled	Regimen	Survival rate	P value	Ref.
EORTC	207	5-FU + radiotherapy	34% (2 yr)	0.099	[72]
		Observation	26% (2 yr)
ESPAC-1	289	5-FU + radiotherapy	10% (5 yr)	-	[73]
		Observation or 5-FU only	20% (5 yr)
RTOG 9704	451	Gemcitabine + radiotherapy	18% (5 yr)	0.120	[147]
		5-FU + radiotherapy	22% (5 yr)

EORTC: European Organization for Research and Treatment of Cancer; ESPAC-1: European Study Group for Pancreatic Cancer 1; RTOG 9704: Radiation Therapy Oncology Group 9704; 5-FU: 5-fluoruracil.